Abstract
1 The pharmacokinetics of single and repeated oral doses of isoxicam, an extensively metabolized drug, were studied in patients with compensated and decompensated hepatic disease.
2 After a single oral dose, isoxicam was slowly absorbed and eliminated (half-life ranging from 10.5 to 53.9 h). Its pharmacokinetics did not differ from those observed in healthy volunteers and were not significantly influenced by the severity of hepatic disease. However, the t½ of isoxicam was found to be inversely (r = -0.700, P < 0.05 n = 14) related to the log γ-glutamyl transpeptidase plasma activity.
3 During chronic oral treatment in patients with compensated hepatic insufficiency, steady-state was achieved after 7-9 days of therapy. The mean elimination half-life of isoxicam in five patients was 42.6 ± 4.5 h, a value which was not statistically different from that obtained in the single dose study.
4 It was concluded that patients with hepatic insufficiency do not require a systematic modification of drug dosage but that long-term treatment should be employed with caution in these patients.
Keywords: pharmacokinetics, hepatic insufficiency, isoxicam, non-steroidal anti-inflammatory drugs
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Borondy P. E., Michniewicz B. M. Metabolic disposition of isoxicam in man, monkey, dog, and rat. Drug Metab Dispos. 1984 Jul-Aug;12(4):444–451. [PubMed] [Google Scholar]
- Daftsios A. C., Johnson E. L., Keeley F. J., Gryczko C., Rawski V. High-performance liquid chromatographic analysis of isoxicam in human plasma and urine. J Chromatogr. 1984 Jan 13;305(1):145–151. doi: 10.1016/s0378-4347(00)83322-8. [DOI] [PubMed] [Google Scholar]
- Esquivel M., Cussenot F., Ogilvie R. I., East D. S., Shaw D. H., Jr Interaction of isoxicam with acetylsalicylic acid. Br J Clin Pharmacol. 1984 Oct;18(4):567–571. doi: 10.1111/j.1365-2125.1984.tb02505.x. [DOI] [PMC free article] [PubMed] [Google Scholar]